WecStrain™ Limosilactobacillus reuteri LR38 for Alleviating Polycystic Ovary Syndrome and Its Application

Abstract

The patent describes the discovery and application of a specific strain of Limosilactobacillus reuteri (LR38), preserved under CGMCC No.24408, which is effective in improving polycystic ovary syndrome (PCOS). The strain addresses PCOS-related symptoms such as metabolic level disorders and abnormal sex hormone levels, providing a potential preventive, alleviating, or therapeutic solution for PCOS.

Technical Field

The invention falls within the realm of microbial culture technology, specifically focusing on the use of Limosilactobacillus reuteri LR38 to treat PCOS. The probiotic is utilized to manufacture products aimed at preventing, alleviating, or treating PCOS.

Background

Polycystic ovary syndrome (PCOS) is a prevalent endocrine metabolic disorder among women of reproductive age, characterized by irregular menstruation, hyperandrogenism, and ovulatory dysfunction, often accompanied by obesity, insulin resistance, hyperinsulinemia, dyslipidemia, and gut microbiota imbalance. This condition poses significant risks for type II diabetes, cardiovascular diseases, metabolic syndrome, and estrogen-related malignancies, severely impacting fertility and quality of life.

Recent studies have highlighted the crucial role of gut microbiota in maintaining overall health and its potential influence on PCOS. Consequently, there is a growing interest in targeting gut microbiota for the management and treatment of PCOS.

Summary of the Invention

The invention aims to provide an effective microbial formulation to improve PCOS by balancing metabolic levels and normalizing sex hormone secretion. Specifically, it introduces a strain of Limosilactobacillus reuteri LR38, isolated from human breast milk, which shows significant efficacy in improving PCOS symptoms through enhancing ovarian health, producing short-chain fatty acids (SCFAs) with antibacterial activity, and boosting gut microbiota diversity.

Detailed Description

1. Isolation and Identification of LR38:

o The strain was isolated from healthy human breast milk in Suzhou, Jiangsu Province.

o It demonstrated superior acid and bile salt tolerance and SCFA production.

2. Preparation of the Culture:

o The strain LR38 is cultured at 30-38°C for 18-24 hours in a medium comprising peptone, beef extract, glucose, lactose, yeast extract, and other nutrients to ensure optimal growth and activity.

3. Probiotic Formulation:

o The probiotic can be formulated into various dosage forms, including lyophilized powder, capsules, tablets, or granules.

o The viable cell count in the probiotic formulation should not be less than 1×10^8 CFU/mL or CFU/g.

4. Synergistic Use with Other Strains:

o The probiotic can be used alone or in combination with other beneficial strains, such as Lactobacillus acidophilus LA88 (CGMCC No.24109).

5. Mechanism of Action:

o LR38 enhances ovarian pathology by reducing cystic follicles, corpus luteum numbers, and testosterone levels.

o It increases SCFA production, which plays a role in immune response and endocrine regulation.

o The strain boosts gut microbiota diversity, which is crucial for overall metabolic health.

Applications

Limosilactobacillus reuteri LR38 can be used to develop various products aimed at preventing, alleviating, or treating PCOS. These products could potentially replace conventional treatments, offering a natural, safe, and effective alternative with fewer side effects.

Conclusion

The Limosilactobacillus reuteri LR38 presents a promising biotherapeutic approach for managing PCOS. Its ability to modulate gut microbiota, enhance ovarian health, and improve metabolic functions positions it as a valuable asset in women's health, particularly for those suffering from PCOS.